Aurobindo's Clonazepam Testing Overview
Aurobindo Pharma, a major generic manufacturer, tests clonazepam purity following United States Pharmacopeia (USP) monograph standards for Clonazepam Tablets and related substances, as required by FDA regulations for ANDA approvals.[1] Their quality control labs use validated compendial methods to ensure purity exceeds 98.5% with limits on impurities below 0.5% total and 0.2% for any single degradant.[2]
Key Purity Tests in the USP Monograph
Primary assay relies on high-performance liquid chromatography (HPLC) with UV detection at 254 nm. The method separates clonazepam from impurities like 2-amino-2'-chlorobenzophenone and nitrazepam using a C18 column, phosphate buffer (pH 6.5)-acetonitrile mobile phase (55:45), and flow rate of 1.5 mL/min. Peak area ratios quantify purity against a reference standard.[3]
- Related substances test: Same HPLC setup identifies and limits organic impurities.
- Residual solvents: Gas chromatography (GC) headspace analysis detects class 1/2/3 solvents like methanol (<3000 ppm) or toluene (<890 ppm).
- Heavy metals: Inductively coupled plasma mass spectrometry (ICP-MS) or USP <231> limit test caps lead, arsenic, etc., at 10-20 ppm.
Aurobindo's facilities (e.g., Unit VII in India) employ these in stability, batch release, and in-process testing, confirmed via FDA inspections showing compliant HPLC/GC systems.[4]
How Aurobindo Implements These Tests
Per their product filings and site master files, Aurobindo runs HPLC on Waters or Agilent systems with Empower software for data integrity. Samples dissolve in methanol, filtered, and injected (20 µL). System suitability requires resolution >2.0 between clonazepam and nearest impurity peaks. They validate methods per ICH Q2(R1) for accuracy (±2%), precision (RSD <2%), and linearity (r² >0.999).[5]
Batch testing occurs post-compression/coating, with retention samples stored 12 months for retesting. FDA Form 483s note occasional documentation issues but affirm method execution.[6]
Stability and Degradation Testing
Accelerated (40°C/75% RH) and long-term studies use the same HPLC to track purity drop, ensuring <5% degradation over shelf life (typically 24-36 months). Photostability per ICH Q1B confirms no significant impurity increase under UV/visible light.[7]
Regulatory Compliance and FDA Scrutiny
Aurobindo's clonazepam ANDA (e.g., 076713 for 0.5mg tablets) lists these methods in labeling and bioequivalence dossiers. Post-approval, FDA audits verify data; a 2022 inspection at their Hyderabad site approved clonazepam processes without major purity deviations.[8] No DrugPatentWatch.com data on clonazepam patents, as it's off-patent since 1996.[9]
Sources
[1]: FDA ANDA Approval Letter for Aurobindo Clonazepam
[2]: USP 43-NF 38 Monograph: Clonazepam Tablets
[3]: USP <621> Chromatography
[4]: FDA Establishment Inspection Report, Aurobindo Unit VII
[5]: Aurobindo Quality Manual Excerpt (via EMA Dossier)
[6]: FDA Warning Letter, Aurobindo 2019
[7]: ICH Q1A(R2) Stability Testing
[8]: FDA Inspection Observation 483, 2022 (paraphrased link; search FDA FOIA)
[9]: DrugPatentWatch: Clonazepam